ABIVAX Société Anonyme/€ABVX
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About ABIVAX Société Anonyme
Abivax Société Anonyme is a clinical-stage biotechnology company headquartered in Paris, France, with a research center in Montpellier and a U.S. office in Waltham, Massachusetts. Founded in December 2013, the company focuses on developing therapeutics that modulate the immune response to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod (formerly ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis and is being prepared for a Phase 2a trial in Crohn's disease. Abivax collaborates closely with the French National Center for Scientific Research (CNRS), the Institut Curie, and the University of Montpellier. In 2015, the company raised €57.7 million in its initial public offering on Euronext Paris, and in October 2023, it raised €232.3 million through an IPO on the Nasdaq Global Market.
Ticker
€ABVX
Sector
Primary listing
PAR
Industry
Biotechnology
Headquarters
Employees
69
Website
ABVX Metrics
BasicAdvanced
€4.5B
-
-€2.94
1.53
-
Price and volume
Market cap
€4.5B
Beta
1.53
52-week high
€61.80
52-week low
€4.51
Average daily volume
52K
Financial strength
Current ratio
1.255
Quick ratio
1.157
Long term debt to equity
-943.538
Total debt to equity
-1,616.535
Interest coverage (TTM)
-12.07%
Profitability
EBITDA (TTM)
-174.394
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,754.30%
Operating margin (TTM)
-1,657.65%
Revenue per employee (TTM)
€150,000
Management effectiveness
Return on equity (TTM)
-196.12%
Valuation
Price to revenue (TTM)
359.118
Price to book
-581.08
Price to tangible book (TTM)
-121.15
Price to free cash flow (TTM)
-24.808
Free cash flow yield (TTM)
-4.03%
Free cash flow per share (TTM)
-2.427
Growth
Revenue change (TTM)
128.98%
Earnings per share change (TTM)
-11.01%
3-year revenue growth (CAGR)
111.82%
10-year revenue growth (CAGR)
40.87%
3-year earnings per share growth (CAGR)
3.28%
10-year earnings per share growth (CAGR)
13.00%
Bulls say / Bears say
Abivax's lead drug candidate, obefazimod, has completed enrollment for Phase 3 ABTECT trials in patients with moderately to severely active ulcerative colitis, indicating progress toward potential market approval. (GlobeNewswire)
Analysts have a 'Buy' consensus rating for Abivax, with a 12-month stock price target of $31.5, suggesting a potential upside of over 300% from the current price. (StockAnalysis)
Abivax has presented multiple abstracts on obefazimod at the 2025 European Crohn’s and Colitis Organization Congress, highlighting its commitment to advancing treatments for inflammatory diseases. (StockTitan)
Abivax reported a net loss of €40.82 million for the quarter ending June 2024, reflecting ongoing financial challenges. (Google Finance)
The company's return on assets (ROA) and return on equity (ROE) are negative, indicating inefficiencies in asset utilization and shareholder equity management. (Fintel)
Abivax's stock price has declined by approximately 40.6% over the past year, underperforming the broader US biotech industry. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ABIVAX Société Anonyme stock?
ABIVAX Société Anonyme (ABVX) has a market cap of €4.5B as of July 30, 2025.
What is the P/E ratio for ABIVAX Société Anonyme stock?
The price to earnings (P/E) ratio for ABIVAX Société Anonyme (ABVX) stock is 0 as of July 30, 2025.
Does ABIVAX Société Anonyme stock pay dividends?
No, ABIVAX Société Anonyme (ABVX) stock does not pay dividends to its shareholders as of July 30, 2025.
When is the next ABIVAX Société Anonyme dividend payment date?
ABIVAX Société Anonyme (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for ABIVAX Société Anonyme?
ABIVAX Société Anonyme (ABVX) has a beta rating of 1.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.